Implications of bilateral free trade agreements on access to medicines.
about
Barriers in the mind: promoting an economic case for mental health in low- and middle-income countriesThe UNAIDS 90-90-90 target: a clear choice for ending AIDS and for sustainable health and developmentTobacco control, global health policy and development: towards policy coherence in global governance.A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countriesDriving a decade of change: HIV/AIDS, patents and access to medicines for all."Trade policy, not morals or health policy": the US Trade Representative, tobacco companies and market liberalization in ThailandTRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines?Management of intellectual property rights in India: An updated review.A proposal for measuring the degree of public health-sensitivity of patent legislation in the context of the WTO TRIPS AgreementScaling up chronic disease prevention interventions in lower- and middle-income countriesTrade policy and health: from conflicting interests to policy coherenceBridging the divide: global governance of trade and health.Intellectual property and access to medicines: an analysis of legislation in Central America.Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition.Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.Trade agreements and drug access: assessment of the impact of the 2009 Peruvian new drug policy on anti-infectives registration and availability
P2860
Q24647113-19FBE904-6979-47A1-AEF6-CF73D77F10B8Q30382647-02E59968-252C-4B70-93CC-1C6A7B84C601Q30413237-CF66A25E-4FDF-4530-B095-D07960DA535EQ34152158-24FC70B2-B448-4AD9-A63A-8D565F434AC4Q34808796-3B29199C-A3B6-407F-BDD8-01DE7755BD4DQ35100285-E1CC306A-A267-4609-96BB-A238D97FF9FBQ35843712-65A44D06-9D1A-4E3C-9F24-E74307A5768AQ35853833-E3462034-840F-440C-92CF-DF72655BB700Q36715307-2BB20E4E-B9FA-4430-BC74-0552BC228298Q36939475-0F9F3BD0-0AD0-4A08-B7B7-D5CCC537EE53Q37084528-7496D99D-7289-4CDD-887F-87B6495886FDQ37314513-4C508D25-87CA-4A76-BC7C-4788C5C109C0Q37370817-604305F1-39E6-4F0A-819E-02F6EB5EB773Q47721296-56ED1731-3658-4726-B39E-8774718DF38EQ52659410-555B1338-1939-45F2-AE2E-B5F9C7BD4F16Q58577034-3380AF33-4485-4242-BDD2-190CEBAA7274
P2860
Implications of bilateral free trade agreements on access to medicines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 May 2006
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Implications of bilateral free trade agreements on access to medicines.
@en
Implications of bilateral free trade agreements on access to medicines.
@nl
type
label
Implications of bilateral free trade agreements on access to medicines.
@en
Implications of bilateral free trade agreements on access to medicines.
@nl
prefLabel
Implications of bilateral free trade agreements on access to medicines.
@en
Implications of bilateral free trade agreements on access to medicines.
@nl
P356
P1476
Implications of bilateral free trade agreements on access to medicines.
@en
P2093
Carlos María Correa
P304
P356
10.2471/BLT.05.023432
P407
P577
2006-05-17T00:00:00Z